Skip to main content
OpenTrials
Completed

NCT Number: NCT00568282

Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

About this study

The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion Criteria:Inclusion Criteria (Cases):

  • Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
  • Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
  • ability to sign informed consent
  • at least 18 years of age

Inclusion criteria

(Controls):

  • no known prior or active malignancy
  • ability to sign informed consent
  • at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years
  • pregnant women

Treatment and study plan

Phlebotomy

Procedure

Standard of care

Other names: blood draw

Primary outcomes

  1. to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells.

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)

Important dates

Study start
2007
Primary completion
2017
Study completion
2021
First posted
Dec 6, 2007
Registry last updated
Jun 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.